Asset Intelligence / Hyperliquid Context
HIMS
Archive-backed market intelligence for HIMS: every HIPERWIRE mover article tied to this asset, plus a client-refreshed live market panel.
HIMS tracks the value of 1 share of common stock in Hims & Hers Health, Inc. Hims & Hers is a health and wellness platform that connects consumers with licensed healthcare providers and offers access to prescription treatments, over-the-counter products, and personalized care across categories such as sexual health, dermatology, weight management, and mental health.
Live Structure
Market Status
Loading current market structure…
- Builderxyz
- Categorystock
- Tracked Marketxyz:HIMS
- Latest TweetOpen
No other live markets from this builder in the current screener.
No same-category alternatives are live in the current screener snapshot.
Archive Summary
Latest Archived Thesis
HIMS Slides Another 9% as JP Morgan, BofA, Jefferies Cut Targets After Q1 Miss
HIMS is extending its post-earnings slide into the cash session, down another 9.02% to $24.93 as JP Morgan, BofA, and Jefferies all cut price targets in the wake of the Q1 miss. The 2026 EBITDA guide was reduced by $25 million at both ends, and BofA flagged that Street estimates calling for $400 million-plus in 2027 EBITDA may need a full reset. The bull case — a Netflix-of-healthcare distribution layer scaling through branded GLP-1 deals — is intact but pushed out, and the tape is repricing that gap.
Archive
All HIMS Mover Articles
HIMS Slides Another 9% as JP Morgan, BofA, Jefferies Cut Targets After Q1 Miss
HIMS is extending its post-earnings slide into the cash session, down another 9.02% to $24.93 as JP Morgan, BofA, and Jefferies all cut price targets in the wake of the Q1 miss. The 2026 EBITDA guide was reduced by $25 million at both ends, and BofA flagged that Street estimates calling for $400 million-plus in 2027 EBITDA may need a full reset. The bull case — a Netflix-of-healthcare distribution layer scaling through branded GLP-1 deals — is intact but pushed out, and the tape is repricing that gap.
HIMS Posts $92M Q1 Loss as Branded GLP-1 Shift Craters Margins
HIMS reported a $92.1 million net loss on $608.1 million of Q1 revenue, missing on the top line and printing -$0.40 EPS against the $0.03 profit consensus. Gross margin compressed 800 basis points to 65% as the company absorbed branded Wegovy and Ozempic costs from the Novo Nordisk distribution deal ahead of the offsetting revenue. Q2 guidance puts adjusted EBITDA margin at just 5 to 8%, well below the 10 to 12% full-year corridor, signaling the transition pain runs deeper than this print. Friday's $31.24 squeeze high is now 16% above the tape.
HIMS Slides 8% Into Tonight's Q1 Print as Friday's Squeeze Unwinds
HIMS is down 8.17% to $28.73 hours before Hims & Hers reports Q1 2026 after the close. Consensus has been sitting at $0.03 EPS for weeks, an 85% collapse from last year's $0.20, with revenue growth decelerating to roughly 5% versus 111% in the same quarter a year ago. The Novo Nordisk Wegovy and Ozempic distribution deal only went live on March 26, so the branded GLP-1 revenue everyone is positioning for shows up in Q2 numbers, not tonight. Friday's squeeze to $31.24 is unwinding into the binary, not breaking.
HIMS Rips 18% Into Q1 Earnings as the GLP-1 Squeeze Stacks Another Leg
HIMS added 18% over 24 hours to $31.24 with the Q1 2026 print landing Monday after the close. Three re-rating events have stacked into the same binary: JPMorgan's late-April Overweight initiation at $35, the Novo Nordisk settlement that lets Hims sell branded Wegovy and Ozempic, and the FDA's tilt toward branded GLP-1 distribution. Options are pricing a roughly 15% post-earnings swing on top of short interest still near 34% of float. The buy side is treating May 11 like the confirmation print on a finished pivot story, not a still-open thesis.
HIMS Adds 6.74% as RFK Jr. Pushes FDA to Unwind 12 Restricted Peptides
Hims & Hers extended its squeeze on April 16 after HHS Secretary Robert F. Kennedy Jr. said the FDA will pull 12 wellness peptides out of Category 2 restrictions and send them to the Pharmacy Compounding Advisory Committee for review in July. The list reads like a Hims product roadmap: BPC-157, KPV, TB-500, MOTs-C, semax, epitalon. Bank of America lifted its target to $25 from $21, pointing at the California peptide facility Hims acquired in February 2025 as ready-to-monetize capacity. Yesterday's move was a technical short squeeze with no catalyst — today's is the fundamental layer bears now have to price in.
HIMS Squeezes Through the 200-Week Moving Average With 46% of Float Short
Hims & Hers ripped 14% on April 15 with no single headline catalyst. The setup told the story: 85 million shares short — 46% of float — and a technical breakout above the 200-week moving average that started Sunday triggered a cascade of forced covering. The stock had been coiling in a $20–$23 range after the March Novo Nordisk settlement, and the break above that range with volume turned a crowded short into a forced unwind.
How to Trade HIMS on Hyperliquid
Hims & Hers Health is the largest direct-to-consumer telehealth platform in the US, connecting millions of subscribers to licensed providers for treatments spanning weight loss, hair care, sexual health, and mental wellness. HIMS is now available as a HIP-3 perpetual futures contract on Hyperliquid, giving traders leveraged exposure to one of the most volatile healthcare stocks of 2026.
Background reading selected from this asset's symbol, builder context, and archived catalyst coverage.
HIP-3 Explained: Builder-Deployed Perps on Hyperliquid
HIP-3 lets anyone deploy a perpetual futures market on Hyperliquid — no approval, no gatekeepers. Builder mechanics, fees, and live markets.
Funding Rates Explained: A Trader's Guide (2026)
Funding rates decide if you pay or earn holding a perp position. How Hyperliquid's hourly funding works, reading rate signals, and cash-and-carry arbitrage.